Pipeline· August 19, 2026 · 16 min read
INTerpath-001 Phase 3: Intismeran Autogene and Keytruda's Post-2028 Strategy
By Ran Chen#Pipeline#Clinical Evidence#Pivotal Trials
Topic
PD-1
PD-1 checkpoint inhibitors, oncology evidence, indication expansion, access, and sequencing.
Approvals· August 13, 2026 · 25 min read
Tudriqev (RP1): FDA Approval of Second Oncolytic Virus for Melanoma
By Ran Chen#FDA Approval#Accelerated Approval#Oncology
Evidence· June 16, 2026 · 12 min read
Checkpoint inhibitors in FAERS: 266,209 adverse-event reports by the numbers
By Ran Chen#PD-1#Real-World Evidence#Label Warnings
Pricing & Access· June 10, 2026 · 10 min read
PD-1/PD-L1 checkpoint inhibitor access landscape in 2026
Pipeline· May 30, 2026 · 11 min read
ASCO 2026 practice-changing results with formulary implications
Pricing & Access· May 27, 2026 · 9 min read